Alnylam Pharmaceuticals vs Sarepta Therapeutics
ALNY and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and SRPT compare
Alnylam Pharmaceuticals is the larger company, worth 13 times as much as Sarepta Therapeutics ($21.0B against $1.6B).
Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −20.4% for Sarepta Therapeutics).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −6.9% at Sarepta Therapeutics.
Sarepta Therapeutics scores higher on the StockData Score (12 against 10 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $21.0B | $1.6B |
| Share price | $156.50 | $14.77 |
| Change, 1 year | −65.2% | −21.5% |
| Change, 5 years | −17.0% | −81.4% |
| Beta (5Y) | 0.92 | 1.71 |
| Employees | 2,500 | 835 |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 | 3 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× | – |
| P/S | 4.2× | 0.8× (better) |
| P/B | 5.8× | 1.0× (better) |
| EV/EBITDA | 16.8× | – |
| P/FCF | 26.0× | 19.1× (better) |
| FCF yield | 3.8% | 5.2% (better) |
| Fair value | $296.91 | $106.96 |
| Margin of safety | 47.3% | 86.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | −20.4% |
| Revenue growth, 5Y average | 49.8% (better) | 32.4% |
| Net income growth (TTM) | 2137% | – |
| EPS growth (TTM) | 2308% | – |
| Profitability | ||
| Gross margin | 77.4% | – |
| Operating margin | 19.5% (better) | −7.3% |
| Net margin | 52.8% (better) | −6.9% |
| FCF margin | 16.1% (better) | 4.1% |
| Return on equity | 127% (better) | −9.3% |
| Return on invested capital | – | −16.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 3.2× | – |
| Current ratio | 2.48 | 4.42 (better) |
| Altman Z-score | 3.62 (better) | −0.32 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.7% | 102% |
| Held by insiders | 0.49% | 5.9% |
| Insider net buying, 12 months | −$26.3M | −$417K (better) |
| Short interest, % of float | 4.1% | 19.4% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.